Cositecan
Basic information
- CAS
203923-89-1- Standard SMILES
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccccc1c2CC[Si](C)(C)C- InChIKey
POADTFBBIXOWFJ-VWLOTQADSA-N- Molecular formula
- C25H28N2O4Si
- Average molar mass
- 448.6 g/mol
- Monoisotopic mass
- 448.18183391
Overview
Cositecan is a pyranoindolizinoquinoline.
Names & identifiers
- Preferred name
- Cositecan
- IUPAC
- (19S)-19-ethyl-19-hydroxy-10-(2-trimethylsilylethyl)-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
- English name
- Karenitecin
- Molecular formula
- C25H28N2O4Si
- Molecular weight
- 448.59
Names & synonyms
KarenitecinCositecan203923-89-1BNP1350KarentecinBNP-1350DTXSID9017434024R60NVC41DB 172NSC710270(4S)-4-Ethyl-4-hydroxy-11-(2-(trimethylsilyl)ethyl)-1,12-dihydro-14H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H)-dionecositecanum
Show more names
MCC 12824(4S)-4-Ethyl-4-hydroxy-11-(2-trimethylsilyl)ethyl)-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-11-[2-(trimethylsilyl)ethyl]-, (4S)-(S)-4-Ethyl-4-hydroxy-11-(2-(trimethylsilyl)ethyl)-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione
RefChem:128190DTXCID2096831(19S)-19-ethyl-19-hydroxy-10-(2-(trimethylsilyl)ethyl)-17-oxa-3,13-diazapentacyclo(11.8.0.02,11.0?,?.01?,2?)henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dioneKarenitecin (Cositecan)UNII-24R60NVC41BNP 1350Cositecan [USAN]Cositecan;BNP 1350
Properties
Computed structural properties
- Topological polar surface area
- 79.7 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 5
- Rotatable bonds
- 4
- Heavy atoms
- 32
- Formal charge
- 0
- Complexity
- 891
Experimental & physicochemical properties
DrugsPharmaceuticals -> Listed in ZINC15
Physicochemical properties
- Boiling point
- 727.2 · 727.2±60.0 °C(Predicted)
- Density
- 1.29 · 1.29±0.1 g/cm3(Predicted)
- storage temp.
- -20 °C · Store at -20°C
- solubility
- Soluble in DMSO
- form
- Solid
- pka
- 11.27 · 11.27±0.20(Predicted)
- color
- Light yellow to yellow
- NCI Dictionary of Cancer Terms
- karenitecin
- FDA UNII
- 24 R60NVC41 · 24R60NVC41
- NCI Drug Dictionary
- karenitecin
- Symbol(GHS)
- 6 · GHS06
- Signal word
- Danger
- Hazard statements
- 301 · H301
- Precautionary statements
- 501 · P501-P270-P264-P301+P310+P330-P405
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Safety data
- Signal word
- Danger
- Symbol(GHS)
- GHS06
- Hazard statements
- H301
- Precautionary statements
- P501-P270-P264-P301+P310+P330-P405
Chemistry & industry
Pharmacology
Mechanism of Action
BNP1350, 7-[(2-trimethylsilyl)ethyl]-20(S)-camptothecin, is a novel semi-synthetic, highly lipophilic, silicon-containing camptothecin and an inhibitor of topoisomerase I. It has been supercomputer engineered for superior oral bioavailability, superior lactone stability, broad anti-tumor activity, increased potency and insensitivity to Pgp/MRP/LRP drug resistance.
Applications
UsesKarenitecin is a topoisomerase I inhibitor, with potent anti-cancer activity.
Additional notes
DefinitionChEBI: Cositecan is a pyranoindolizinoquinoline.
Related reactions
1 records
Compound notes
Loading…